spacer
home > ict > winter 2019 > improving outcomes in diabetes research
PUBLICATIONS
International Clinical Trials

Improving Outcomes in Diabetes Research

Diabetes is often referred to as an epidemic, with an estimated 415 million adults worldwide living with the condition, according to the International Diabetes Federation Diabetes Atlas – approximately 1 in 11 of the adult population (1). What’s more, this figure is expected to rise to 642 million people worldwide by 2040. With a reported 46% of people with diabetes undiagnosed, these figures are, realistically, much higher.

With so much of the population suffering, pharmaceutical companies are continuing to invest in research into this condition in a bid to bring new and improved treatments to market across the globe. With this in mind, this article will discuss the current status of diabetes clinical research. In particular, it will provide an overview of the current diabetes landscape, including the types of disease and condition management, as well as the challenges of clinical research. Putting the person with diabetes at the heart of the development process will demonstrate how sponsors can implement patient-centric electronic data capture solutions which improve the user experience and support better study outcomes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Katie Garner is the Therapeutic Areas Advisor at CRF Bracket. She is responsible for providing specific therapeutic advice and supporting the therapeutic, sales, marketing, and product development teams. Previously, Katie worked as a Project Manager for a health outcomes consultancy and at the NHS Purchasing and Supply Agencies Centre for Evidence-Based Purchasing. She has also worked for the Medicine and Healthcare products Regulatory Agency as a Senior Medical Device Specialist, responsible for the safety and regulation of in vitro diagnostic and contraceptive medical devices.
spacer
Katie Garner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

[Pamplona, November 26 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.
More info >>

White Papers

Streamlining patient recruitment using EHR data

The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement